ALT (Altimmune) Tax Rate % : 0.00% (As of Dec. 2024)

View and export this data going back to 2005. Start your Free Trial

What is Altimmune Tax Rate %?

Tax Rate % is calculated as Tax Expense divided by its Pre-Tax Income. Altimmune's Tax Expense for the three months ended in Dec. 2024 was $0.00 Mil. Altimmune's Pre-Tax Income for the three months ended in Dec. 2024 was $-23.18 Mil. Therefore, Altimmune's Tax Rate % for the quarter that ended in Dec. 2024 was 0.00%.

Altimmune Tax Rate % Historical Data

The historical data trend for Altimmune's Tax Rate % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Altimmune Tax Rate % Chart

Altimmune Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Tax Rate %

Get a 7-Day Free Trial

9.95

0.23

Altimmune Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Tax Rate %	Get a 7-Day Free Trial															-	-	-	-	-

Altimmune Tax Rate % Calculation

Tax Rate % is the ratio of tax expense divided by pretax income, usually presented in percent.

Altimmune's Tax Rate % for the fiscal year that ended in Dec. 2024 is calculated as

Tax Rate %	=	Tax Expense (A: Dec. 2024 )	/	Pre-Tax Income (A: Dec. 2024 )
	=	0	/	-95.059
	=	0.00 %

Altimmune's Tax Rate % for the quarter that ended in Dec. 2024 is calculated as

Tax Rate %	=	Tax Expense (Q: Dec. 2024 )	/	Pre-Tax Income (Q: Dec. 2024 )
	=	0	/	-23.18
	=	0.00 %

Altimmune Tax Rate % Related Terms

Thank you for viewing the detailed overview of Altimmune's Tax Rate % provided by GuruFocus.com. Please click on the following links to see related term pages.

Altimmune Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Altimmune Inc (NAS:ALT) » Definitions » Tax Rate %

Comparable Companies

Traded in Other Exchanges

ALT1:Mexico 0A4C:UK 3G0:Germany 3G0:Germany

Address

910 Clopper Road, Suite 201S, Gaithersburg, MD, USA, 20878

Website

https://www.altimmune.com

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Executives

Catherine A. Sohn	director	C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
David Drutz	director	8601 SIX FORKS ROAD, SUITE 160, RALEIGH NC 27615
Richard I Eisenstadt	officer: Chief Financial Officer	4819 EMPEROR BOULEVARD, SUITE 400, DURHAM NC 27703
Matthew Scott Harris	officer: Chief Medical Officer	C/O ALTIMMUNE, INC., 910 CLOPPER ROAD, SUITE 201S, GAITHERSBURG MD 20878
Raymond M Jordt	officer: Chief Business Officer	ALTIMMUNE, INC., 910 CLOPPER ROAD, SUITE 201S, GAITHERSBURG MD 20878
Wayne Pisano	director	C/O PROVENTION BIO, INC., P.O. BOX 666, OLDWICK NJ 08858
Vipin K Garg	director, officer: President and CEO	4819 EMPEROR BOULEVARD, SUITE 400, DURHAM NC 27703
John Gill	director	C/O PHARMATHENE, INC, ONE PARK PLACE, SUITE 450, ANNAPOLIS MD 21401
M Scot Roberts	officer: Chief Scientific Officer	910 CLOPPER ROAD, SUITE 201S, GAITHERSBURG MD 20878
Diane Jorkasky	director	60 MANOR AVENUE, WELLESLEY MA 02482
Philip Hodges	director	19 FIRSTFIELD RD., SUITE 200, GAITHERSBURG MD 20878
Vhcp Management Iii, Llc	10 percent owner	7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018
Venrock Healthcare Capital Partners Ii, L.p.	10 percent owner	7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018
Venrock Healthcare Capital Partners Iii, L.p.	10 percent owner	530 FIFTH AVENUE, 22ND FLOOR, NEW YORK NY 10036
Vhcp Co-investment Holdings Iii, Llc	10 percent owner	7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018